NCT02833142View on ClinicalTrials.gov

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Multiple SclerosisAcute Optic Neuritis
Interventions
DRUG

BIIB033 (opicinumab)

Trial Locations (1)

53704

Research Site, Madison

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY